Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA901 + sargramostim
- Development stage
- Phase 2
- Lead developer
- Immatics US, Inc.
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
IMA901 + sargramostim is a combination therapy investigated primarily for the treatment of advanced renal cell carcinoma. IMA901 is a multipeptide cancer vaccine designed to stimulate an immune response against tumor-associated antigens. Sargramostim (brand name Leukine) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that acts as an immunomodulatory adjuvant by promoting the production and activation of dendritic cells and other immune cells. In this combination, sargramostim enhances the immunogenicity of the peptide vaccine by recruiting and activating antigen-presenting cells at the site of vaccination[2][5]. The primary indication studied has been advanced renal cell carcinoma, with clinical trials reaching phase 3[5].
- Other names
- GM-CSFgranulocyte-macrophage colony-stimulating factor
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)MHC I (MHC class I})CD8A (CD8 alpha/beta Coreceptor)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on IMA901 + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA901 + sargramostim.